TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20095806
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg glucocorticosteroids for 5 days
Study: 19029466
Drug: torcetrapib/atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: torcetrapib/atorvastatin
Study: 19029466
Drug: atorvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin monotherapy
Study: 1985164
Drug: Parenteral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Parenteral methotrexate (MTX group)
Study: 6849644
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin sulfate (7.5 mg/kg, IM) - single dose
Study: 6849644
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin sulfate (7.5 mg/kg, IM) - two doses (5 1/2 to 12 hours apart)
Study: 6849644
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin sulfate (7.5 mg/kg, IM) - second dose given 9 to 12 hours after first
Study: 17440420
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (12 mL/kg)
Study: 17440420
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (6 mL/kg)
Study: 27147264
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761® (240 mg daily)
Study: 23011014
Drug: Generic artemether/lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic artemether/lumefantrine 20/120 mg tablets
Study: 19414437
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min, group A, n = 13)
Study: 19414437
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min) and ET‐B receptor blocker BQ‐788 (10 nmol/min, group AB, n = 13)
Study: 19414437
Drug: ET‐receptor blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐receptor blockade (both groups)
Study: 12816266
Drug: Aprotinin (30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (30,000 KIU/kg on induction and 10,000 KIU/kg/hr infusion until surgery completion, max 8 hours)
Study: 8635612
Drug: Ultra-low-dose (75IU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose (75IU) human menopausal gonadotrophin (hMG)
Study: 1300037
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine (Cim)
Study: 1300037
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ranitidine (Ran)
Study: 31892674
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent with laser
Study: 31892674
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent only
Study: 31892674
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo prescription)
Study: 29199720
Drug: Capecitabine (1650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1650 mg/m2 on RT days throughout the course of radiotherapy)
Study: 29199720
Drug: 5FU (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU (500 mg/m2 on RT days #1‐#5 and #21‐#25)
Study: 24488721
Drug: Tideglusib 600
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tideglusib 600 mg
Study: 24488721
Drug: Tideglusib 800
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tideglusib 800 mg
Study: 22167570
Drug: Atorvastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (1 mg/kg)
Study: 22167570
Drug: Rosuvastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (1 mg/kg)
Study: 22167570
Drug: Simvastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (1 mg/kg)
Study: 22167570
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and simvastatin in healthy human subjects
Study: 16189333
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.5% bupivacaine with midazolam 50 microg x kg(‐1)
Study: 16189333
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.5% bupivacaine
Study: 14621278
Drug: Antisecretory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisecretory factor (AF) treatment as an additive to conventional UC medication
Study: 12927001
Drug: Sertraline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (up to 100 mg/day)
Study: 10804075
Drug: Nortriptyline (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (low vs. regular doses)
Study: 10211012
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg
Study: 1298491
Drug: Paracetamol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1,000 mg
Study: 20502743
Drug: Nasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal insulin
Study: 15288319
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics (10-day course)
Study: 8479715
Drug: Eye muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye muscle reflectivity measurement in responders to treatment
Study: 3317344
Drug: Yeast-derived hepatitis
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived hepatitis B vaccine
Study: 3317344
Drug: Partly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partly purified recombinant vaccines
Study: 27191766
Drug: Ticagrelor with
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor with moderate CYP3A inhibitors
Study: 27191766
Drug: Ticagrelor at
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor at treatment initiation (visit 1)
Study: 17609248
Drug: Remifentanil step‐up/‐down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 0, 2, 6, 2, 0 ng ml(‐1)
Study: 17609248
Drug: Remifentanil step‐up/‐down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 6, 2, 0, 2, 6 ng ml(‐1)
Study: 12192713
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of diluted injectable quinimax at a dose of 12.5 mg/kg every 12 hours for 72 hours.
Study: 12192713
Drug: Intrarectal (IR)
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal (IR) administration of diluted injectable quinimax at a dose of 15 mg/kg every 12 hours for 72 hours.
Study: 8130028
Drug: Allopurinol (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (1200 mg in two divided doses)
Study: 2528306
Drug: Mivacurium bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium bolus dose 0.15 mg/kg
Study: 2528306
Drug: Mivacurium bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium bolus dose 0.25 mg/kg
Study: 2528306
Drug: Mivacurium bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium bolus dose (both 0.15 mg/kg and 0.25 mg/kg) with no additional mivacurium
Study: 2528306
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion adjusted to depress twitch response by approximately 95%
Study: 2528306
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion rates
Study: 1161344
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (oral sodium bicarbonate treatment when base excess > -8 mEq/liter or suspected acidosis)
Study: 1161344
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (oral sodium bicarbonate treatment maintaining base excess within 1 SD of normal)
Study: 1161344
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (oral sodium bicarbonate treatment)
Study: 1161344
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (oral sodium bicarbonate treatment)
Study: 25452062
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation medication
Study: 31816049
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of smoking cessation medications
Study: 25524432
Drug: Metformin/Sulfonylurea (Control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/Sulfonylurea (Control)
Study: 25524432
Drug: Metformin/Sulfonylurea (Control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/Sulfonylurea (Control, Women)
Study: 25524432
Drug: Metformin/Sulfonylurea (Control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/Sulfonylurea (Control, Men)
Study: 21130194
Drug: Pandemic H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic H1N1 vaccine first, followed by seasonal vaccine 21 days later
Study: 21130194
Drug: Seasonal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal vaccine first, followed by pandemic H1N1 vaccine 21 days later
Study: 21130194
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines administered simultaneously
Study: 19943971
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and vigorous intensity exercise
Study: 17296639
Drug: Long-term targeted
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term targeted therapy
Study: 16113556
Drug: Betamethasone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (two doses, 24 hours apart)
Study: 8709687
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg daily, intramuscularly, for three doses)
Study: 1770216
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 2 gm/day for 30 days
Study: 6800629
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (oral feeding)
Study: 28374218
Drug: PAST (treatment-as-usual)
Normalized name: Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAST (treatment-as-usual)
Study: 26745346
Drug: Polish treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polish treatment group
Study: 22782571
Drug: CNE™ low
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNE™ low dose (CNE4)
Study: 22782571
Drug: CNE™ high
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNE™ high dose (CNE8)
Study: 19897418
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus cetuximab (400 mg/m2 initial dose, followed by seven weekly doses at 250 mg/m2)
Study: 18445258
Drug: Peer-mediated interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peer-mediated interventions (STI/HIV education, condoms, facilitated HIV testing, treatment and care services)
Study: 10551685
Drug: Thrombolytic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrombolytic administration
Study: 10520778
Drug: Adjunctive percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive percutaneous transluminal coronary angioplasty (PTCA) of the culprit artery
Study: 7720766
Drug: FCH-free GTN
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCH-free GTN spray with low ethanol content (TL)
Study: 7720766
Drug: FCH-containing GTN
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCH-containing GTN spray (R)
Study: 7720766
Drug: FCH-free GTN
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCH-free GTN spray with higher ethanol content (TH)
Study: 19627887
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (group 2)
Study: 9256119
Drug: Idarubicin 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 12 mg/m2/d for 3 days in combination with fludarabine and cytarabine
Study: 9256119
Drug: Fludarabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and cytarabine (loading dose of 10.5 mg/m2 followed by continuous infusion of 30.5 mg/m2/24 hours for 48 hours, followed by cytarabine loading dose 390 mg/m2, then continuous infusion 101 mg/m2/h for 72 hours)
Study: 3321925
Drug: 0.75 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 micrograms alpha-calcidol (1 alpha(OH)D3) daily
Study: 19770753
Drug: Low-dose phospholipid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phospholipid emulsion (850 mg/kg)
Study: 19770753
Drug: High-dose phospholipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phospholipid emulsion (1350 mg/kg)
Study: 12616671
Drug: Risperidone 0.5
Normalized name: risperidone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5 mg twice daily
Study: 30109588
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg once daily
Study: 12616671
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Risperidone 0.5 mg twice daily and Donepezil 5 mg once daily)
Study: 10883569
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (meditation-relaxation)
Study: 8256189
Drug: Gentamicin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1.5 mg/kg every 8 hours) plus Mezlocillin (3 grams every 4 hours)
Study: 3543180
Drug: Oral decongestant-antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral decongestant-antihistamine combination and mucolytic preparation
Study: 11853215
Drug: Marina (artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marina (artificial mineral water containing K+ and Mg2+ ions), 4 x 200 ml daily for 7 days
Study: 7915076
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg.kg‐1) followed by vecuronium (0.15 mg.kg‐1)
Study: 7915076
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no succinylcholine, vecuronium 0.15 mg.kg‐1)
Study: 7915076
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (supplemental vecuronium 0.04 mg.kg‐1)
Study: 2656959
Drug: Acetaminophen, 10
Normalized name: Acetaminophen, 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 10 mg/kg/dose, given at 8 AM, 12 PM, 4 PM, and 8 PM for 4 days.
Study: 5015033
Drug: Hyoscine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine 0.4 mg
Study: 5015033
Drug: Hyoscine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine 0.6 mg
Study: 24421235
Drug: Sequential enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential enteral nutrition (Group A)
Study: 8913408
Drug: Acarbose in
Normalized name: Product containing acarbose in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose in combination with sulfonylureas
Study: 4083302
Drug: 7 P.M.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 P.M. dosing with 800 mg of Uniphyl
Study: 29557250
Drug: Placebo (saline-soaked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline-soaked gel foam)
Study: 25357174
Drug: 1,320-nm Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,320-nm Nd:YAG laser treatment
Study: 25357174
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment of cryogen cooling only
Study: 18411009
Drug: Daily Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Sleep Interference Scale (DSIS)
Study: 12969711
Drug: N,O-carboxymethylchitosan (NOCC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N,O-carboxymethylchitosan (NOCC) - 200 mL of 1% NOCC gel followed by 100 mL of 2% NOCC solution
Study: 22513879
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injections
Study: 1378783
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release gallopamil 100mg twice daily
Study: 3514487
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg chlorthalidone
Study: 3514487
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 50 mg atenolol and 12.5 mg chlorthalidone
Study: 3514487
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol-chlorthalidone
Study: 9863872
Drug: Dideoxynucleoside monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideoxynucleoside monotherapy (zidovudine)
Study: 9863872
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (zidovudine, zalcitabine, didanosine)
Study: 7897523
Drug: 8 drugs
Normalized name: goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 drugs in 1 day regimen followed by high-dose methotrexate (12 g/m2)
Study: 7897523
Drug: Postirradiation chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postirradiation chemotherapy with four 8/1 courses monthly
Study: 7897523
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of radiation doses in Group B
Study: 7897523
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment including sandwich chemotherapy
Study: 2495900
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg sodium cromoglycate metered dose inhaler
Study: 2495900
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sodium cromoglycate metered dose inhaler
Study: 799981
Drug: New analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New analgesic compound (propoxyphene, acetaminophen, caffeine, hydroxyzine)
Study: 799981
Drug: Plain acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain acetaminophen
Study: 16511927
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment approach (control group)
Study: 27635609
Drug: Cytoflavin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (20 ml per 400 ml of 5% glucose solution, intravenously, 1 time a day for 10 days, then 2 tablets 2 times a day for a month)
Study: 16188154
Drug: Concurrent radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent radio-chemotherapy (NVB + DDP plus radiotherapy)
Study: 16188154
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (NVB + DDP)
Study: 12358338
Drug: Nedocromil (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil (two puffs of 2 mg)
Study: 12358338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nedocromil and salbutamol
Study: 2176235
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg twice (group A)
Study: 2176235
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once (group B)
Study: 7000106
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) 12.5 mg kg‐1
Study: 7000106
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) 25 mg kg‐1
Study: 7000106
Drug: Oxycodone 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.15 mg kg‐1
Study: 30370450
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU) after memory retrieval
Study: 30370450
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU) without retrieval
Study: 28024952
Drug: Prime-boost EVD
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prime-boost EVD vaccine
Study: 21950726
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg/d
Study: 17694386
Drug: Daily low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low dose plasma exchange
Study: 15780697
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment (not specified dosage or duration)